Nicotinic acetylcholine receptor
Complex group in Pediculus humanus capitis that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
- Genes: 6
Who is on it, and how far along
Every drug ChEMBL records acting on 8232002, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Comparison of Topical Permethrin 5% and Spinosad 0.9% for Scabies Treatment | Spinosad | Not applicable | Not yet recruiting | University of Faisalabad | Nov 13, 2026 |
| A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis | Spinosad | Phase 2 | Not yet recruiting | Aperta Biosciences, LLC | Oct 29, 2026 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364023, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets